These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15995794)

  • 1. Cevimeline hydrochloride improved cholinergic dysfunction in a patient with pure autonomic failure.
    Ogata A; Kitano M; Sano H
    J Neurol; 2006 Jan; 253(1):119-20. PubMed ID: 15995794
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical significance of cevimeline hydrochloride in the treatment of dry mouth in patients with Sjögren's syndrome].
    Ogawa N; Shimoyama K; Karasawa H; Fukushima T; Masaki Y; Wano Y; Hirose Y; Sugai S
    Nihon Rinsho Meneki Gakkai Kaishi; 2004 Oct; 27(5):330-7. PubMed ID: 15559322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effectiveness of cevimeline hydrochloride on dry cough in Sjögren's syndrome].
    Nishinarita M; Hanzawa M; Iikuni N; Ota S
    Nihon Rinsho Meneki Gakkai Kaishi; 2004 Apr; 27(2):99-102. PubMed ID: 15164930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cevimeline (Evoxac) for dry mouth.
    Med Lett Drugs Ther; 2000 Aug; 42(1084):70. PubMed ID: 10932302
    [No Abstract]   [Full Text] [Related]  

  • 5. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial.
    Fife RS; Chase WF; Dore RK; Wiesenhutter CW; Lockhart PB; Tindall E; Suen JY
    Arch Intern Med; 2002 Jun; 162(11):1293-300. PubMed ID: 12038948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren's syndrome.
    Fox RI
    Adv Exp Med Biol; 2002; 506(Pt B):1107-16. PubMed ID: 12614037
    [No Abstract]   [Full Text] [Related]  

  • 7. Sjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment.
    Komai K; Shiozawa K; Tanaka Y; Yoshihara R; Tanaka C; Sakai H; Yamane T; Murata M; Tsumiyama K; Hashiramoto A; Shiozawa S
    Mod Rheumatol; 2009; 19(4):416-9. PubMed ID: 19452244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study.
    Ono M; Takamura E; Shinozaki K; Tsumura T; Hamano T; Yagi Y; Tsubota K
    Am J Ophthalmol; 2004 Jul; 138(1):6-17. PubMed ID: 15234277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a muscarinic M3 receptor agonist on gastric motility.
    Chiba T; Kudara N; Sato M; Inomata M; Orii S; Suzuki K
    J Gastroenterol Hepatol; 2007 Nov; 22(11):2039-41. PubMed ID: 17914991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cevimeline on radiation-induced salivary gland dysfunction and AQP5 in submandibular gland in mice.
    Takakura K; Takaki S; Takeda I; Hanaue N; Kizu Y; Tonogi M; Yamane GY
    Bull Tokyo Dent Coll; 2007 May; 48(2):47-56. PubMed ID: 17978545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cevimeline on salivary components in patients with Sjögren syndrome.
    Suzuki K; Matsumoto M; Nakashima M; Takada K; Nakanishi T; Okada M; Ohsuzu F
    Pharmacology; 2005 May; 74(2):100-5. PubMed ID: 15722648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cevimeline.
    Weber J; Keating GM
    Drugs; 2008; 68(12):1691-8. PubMed ID: 18681491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the effectiveness and adverse effects of pilocarpine and cevimeline in patients with hyposalivation.
    Farag AM; Holliday C; Cimmino J; Roomian T; Papas A
    Oral Dis; 2019 Nov; 25(8):1937-1944. PubMed ID: 31520497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia.
    Witsell DL; Stinnett S; Chambers MS
    Head Neck; 2012 Aug; 34(8):1136-42. PubMed ID: 22231734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation.
    Omori Y; Asari T; Maruyama K; Kusama H; Kojima M; Shibata N
    Arzneimittelforschung; 2003; 53(5):342-50. PubMed ID: 12854361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of muscarinic agonists in the treatment of Sjögren's syndrome.
    Fox RI; Konttinen Y; Fisher A
    Clin Immunol; 2001 Dec; 101(3):249-63. PubMed ID: 11726216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.
    Petrone D; Condemi JJ; Fife R; Gluck O; Cohen S; Dalgin P
    Arthritis Rheum; 2002 Mar; 46(3):748-54. PubMed ID: 11920411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological approaches to targeting muscarinic acetylcholine receptors.
    Matera C; Tata AM
    Recent Pat CNS Drug Discov; 2014; 9(2):85-100. PubMed ID: 25413004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idiopathic CD4+ lymphocytopenia and Sjogren syndrome.
    Wladis EJ; Kapila R; Chu DS
    Arch Ophthalmol; 2005 Jul; 123(7):1012. PubMed ID: 16009850
    [No Abstract]   [Full Text] [Related]  

  • 20. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
    Arisawa H; Imai E; Fujise N; Fukui K; Masunaga H
    Arzneimittelforschung; 2002; 52(1):14-20. PubMed ID: 11838269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.